A Multicentre Propensity Matched Analysis of Clinical Outcomes With the ACURATE Neo2 Transcatheter Aortic Valve
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70234 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Christopher J Broyd und 18 weiteren Autor:innen. Beteiligte Einrichtung: University Sussex Hospitals, Brighton, UK. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Aortic Valve, Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis. Die Arbeit nennt 28 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Introduction
Recent data from a large randomized trial suggested less advantageous outcomes following TAVI with the ACURATE Neo2 valve. However, this valve was more appropriately used selectively in patients with smaller annuli and lesser degrees of aortic valve calcification.
Methods
Data from the four highest‐volume ACURATE Neo2 implanting sites in the UK were analyzed to compare outcomes between patients treated with the ACURATE Neo2 valve and the Edwards Sapien or Evolut Pro valves. Baseline data was collected at the time of TAVI and outcome obtained from individual patient records. 1‐to‐1 logit propensity matching with replacement was performed and outcome and survival rates compared. The primary outcome was a composite of death, stroke or cardiac readmission at 1‐year.
Results
A total of 1277 patients were included for analysis, 500 of whom received the ACURATE Neo2. Median follow‐up was 859 days (95% CI: 441–1062). The ACURATE Neo2 valve was not associated with the composite event ( p = 0.56) or its subcomponents. Propensity score matching generated 481 matched pairs which did not differ in terms of the composite end point (15.6% vs. 17.9%, p = 0.34) or the individual subcomponents at 1 year. No difference was seen in survival curves ( p = 0.81 for composite end point).
Conclusion
The ACURATE Neo2 valve was a good valve choice for selected patients with severe aortic stenosis. With appropriate patient selection and experienced implanting teams, the ACURATE Neo2 valve led to outcomes equivalent to the other major valve platforms in use today.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Sussex Hospitals, Brighton, UK.
- Brighton and Sussex Medical School, Brighton, UK.
- Liverpool Heart Centre, Liverpool, UK.
- Essex Cardiothoracic Centre, Basildon, UK.
- Glenfield Hospital, Leicester, UK.
- Anglia Ruskin University, Cambridge, UK.
ORCID-Profile: Timothy J Bagnall
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Broyd, C. J., Bagnall, T. J., Singal, A., Fawaz, S., Olusan, A., Wong, S. F., Artani, M., Chani, A., Eltayeb, M., Abouelasaad, M., Kovac, J., Jagathesan, R., Stables, R., Sandhu, K., Cockburn, J., Rajendra, R., Cook, C., Appleby, C., & Hildick-Smith, D. (2025). A Multicentre Propensity Matched Analysis of Clinical Outcomes With the ACURATE Neo2 Transcatheter Aortic Valve. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70234
Vancouver
Broyd CJ, Bagnall TJ, Singal A, Fawaz S, Olusan A, Wong SF, et al. A Multicentre Propensity Matched Analysis of Clinical Outcomes With the ACURATE Neo2 Transcatheter Aortic Valve. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70234
BibTeX
@article{Broyd2025,
author = {Broyd, Christopher J and Bagnall, Timothy J and Singal, Aayush and Fawaz, Samer and Olusan, Adeogo and Wong, Siu-Fung and Artani, Moiz and Chani, Ashni and Eltayeb, Mohamed and Abouelasaad, Mohamed and Kovac, Jan and Jagathesan, Rohan and Stables, Rodney and Sandhu, Kully and Cockburn, James and Rajendra, Raj and Cook, Christopher and Appleby, Clare and Hildick-Smith, David},
title = {A Multicentre Propensity Matched Analysis of Clinical Outcomes With the ACURATE Neo2 Transcatheter Aortic Valve},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70234}
}
EUVIMED